Reginald Clayton

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi request reprint Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells
    Reginald Clayton
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, 2800 Mechelen, Belgium
    J Virol Methods 139:17-23. 2007
  2. ncbi request reprint A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion
    Géry Dams
    Tibotec BVBA, Mechelen, Belgium
    J Biomol Screen 12:865-74. 2007
  3. pmc Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors
    Olivia Goethals
    Tibotec BVBA, Mechelen, Belgium
    J Virol 82:10366-74. 2008
  4. doi request reprint Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes
    Reginald Clayton
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, Mechelen, Belgium
    Antiviral Res 84:142-9. 2009
  5. doi request reprint MAPPIT as a high-throughput screening assay for modulators of protein-protein interactions in HIV and HCV
    Bertrand Van Schoubroeck
    Tibotec Inc, Mechelen, Belgium
    Methods Mol Biol 812:295-307. 2012

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells
    Reginald Clayton
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, 2800 Mechelen, Belgium
    J Virol Methods 139:17-23. 2007
    ..These data further underline the potential of monoclonal antibodies as targeting agents, and offer new insights into the possibility of F105 as a targeting moiety for the delivery of antiretroviral drugs to HIV-1 infected cells...
  2. ncbi request reprint A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion
    Géry Dams
    Tibotec BVBA, Mechelen, Belgium
    J Biomol Screen 12:865-74. 2007
    ..This study's observations substantiate the expediency of time-resolved FRET-based assays to identify small-molecule inhibitors of protein-protein interactions...
  3. pmc Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors
    Olivia Goethals
    Tibotec BVBA, Mechelen, Belgium
    J Virol 82:10366-74. 2008
    ..These data broaden the understanding of antiviral resistance against integrase inhibitors and may give insight facilitating the discovery of second-generation compounds...
  4. doi request reprint Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes
    Reginald Clayton
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, Mechelen, Belgium
    Antiviral Res 84:142-9. 2009
    ..This approach to targeted delivery of antiretroviral compounds may enable the design of drug regimens for patients that allow increased therapeutic adherence and less toxic treatment of HIV infection...
  5. doi request reprint MAPPIT as a high-throughput screening assay for modulators of protein-protein interactions in HIV and HCV
    Bertrand Van Schoubroeck
    Tibotec Inc, Mechelen, Belgium
    Methods Mol Biol 812:295-307. 2012
    ....